Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Regulation of MCP-1 chemokine transcription by p53

Open access
Hacke, Katrin, Rincon-Orozco, Bladimiro, Buchwalter, Gilles, Siehler, Simone Y., Wasylyk, Bohdan, Wiesmüller, Lisa, Rösl, Frank · 2010 · Molecular Cancer

Abstract

Background: Our previous studies showed that the expression of the monocyte-chemoattractant protein (MCP)-1, a chemokine, which triggers the infiltration and activation of cells of the monocyte-macrophage lineage, is abrogated in human papillomavirus (HPV)-positive premalignant and malignant cells.In silico analysis of the MCP-1 upstream region proposed a putative p53 binding side about 2.5 kb upstream of the transcriptional start. The aim of this study is to monitor a physiological role of p53 in this process. Results: The proposed p53 binding side could be confirmed in vitro by electrophoretic-mobility-shift assays and in vivo by chromatin immunoprecipitation. Moreover, the availability of p53 is apparently important for chemokine regulation, since TNF-α can induce MCP-1 only in human keratinocytes expressing the viral oncoprotein E7, but not in HPV16 E6 positive cells, where p53 becomes degraded. A general physiological role of p53 in MCP-1 regulation was further substantiated in HPV-negative cells harboring a temperature-sensitive mutant of p53 and in Li-Fraumeni cells, carrying a germ-line mutation of p53. In both cases, non-functional p53 leads to diminished MCP-1 transcription upon TNF-α treatment. In addition, siRNA directed against p53 decreased MCP-1 transcription after TNF-α addition, directly confirming a crosstalk between p53 and MCP-1. Conclusion: These data support the concept that p53 inactivation during carcinogenesis also affects immune surveillance by interfering with chemokine expression and in turn communication with cells of the immunological compartment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-9-82

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MCP-1 expression in HPV16 immortalized human keratinocytes and in vitro binding activity of wild-type p53 at the MCP-1 regulatory region. (A) Upper panel: RT-PCR for MCP-1 and GAPDH in HPV16 E6-, E7-, and E6/7 immortalized human foreskin keratinocytes. Cells were treated with TNF-α (250 U/ml) (+) for 6 h. (-) untreated control. The RT-PCR products were separated on 1.5% agarose gel. Lower panel: Western blot analysis of p53. Cytosolic extracts (50 μg per lane) were separated in a 12% SDS-PAGE. Equal loading was confirmed using an actin specific antibody. (B) RT-PCR for MCP-1, p53 and GAPDH in E7-immortalized keratinocytes after lentiviral p53 shRNA delivery. Cells were treated as described in panel A. (C) Schematic overview of the MCP-1 gene. The region -2750 to -2150 bp upstream of the MCP-1 start site harbors two NFκB and one AP-1 binding site. The in silico identified putative p53 binding site (-2422/-2391) relative to NFκB and AP-1 is indicated. Black boxes: exon I-III; white box: polyadenylation site (poly-A), (striped grey box): 3'-regulatory region. (D) Left panel: Electrophoretic mobility shift assay (EMSA): 60 ng of recombinant p53 protein was incubated with [32P]-labeled double-stranded oligonucleotides harboring the wild-type p53-specific RGC-site, the mutated version thereof and the putative MCP-1 p53 binding site, respectively. In addition, binding was also performed in the presence of 200 ng of BSA, anti-GAPDH, DO-1, PAb1801, or PAb421. The positions of free probe, DNA in complex with p53, and DNA in complex with p53 plus supershifting antibodies are indicated by arrows. (D) Right panel: EMSA: comparative binding analysis for wild-type p53 (wtp53) using specific RGC and non-specific RGC mutated versus MCP-1 DNA. DNA binding activities of wild-type p53 (wtp53), p53pro248 and p53pro273 mutants are indicated.
Figure 1 MCP-1 expression in HPV16 immortalized human keratinocytes and in vitro binding activity of wild-type p53 at the MCP-1 regulatory region. (A) Upper panel: RT-PCR for MCP-1 and GAPDH in HPV16 E6-, E7-, and E6/7 immortalized human foreskin keratinocytes. Cells were treated with TNF-α (250 U/ml) (+) for 6 h. (-) untreated control. The RT-PCR products were separated on 1.5% agarose gel. Lower panel: Western blot analysis of p53. Cytosolic extracts (50 μg per lane) were separated in a 12% SDS-PAGE. Equal loading was confirmed using an actin specific antibody. (B) RT-PCR for MCP-1, p53 and GAPDH in E7-immortalized keratinocytes after lentiviral p53 shRNA delivery. Cells were treated as described in panel A. (C) Schematic overview of the MCP-1 gene. The region -2750 to -2150 bp upstream of the MCP-1 start site harbors two NFκB and one AP-1 binding site. The in silico identified putative p53 binding site (-2422/-2391) relative to NFκB and AP-1 is indicated. Black boxes: exon I-III; white box: polyadenylation site (poly-A), (striped grey box): 3'-regulatory region. (D) Left panel: Electrophoretic mobility shift assay (EMSA): 60 ng of recombinant p53 protein was incubated with [32P]-labeled double-stranded oligonucleotides harboring the wild-type p53-specific RGC-site, the mutated version thereof and the putative MCP-1 p53 binding site, respectively. In addition, binding was also performed in the presence of 200 ng of BSA, anti-GAPDH, DO-1, PAb1801, or PAb421. The positions of free probe, DNA in complex with p53, and DNA in complex with p53 plus supershifting antibodies are indicated by arrows. (D) Right panel: EMSA: comparative binding analysis for wild-type p53 (wtp53) using specific RGC and non-specific RGC mutated versus MCP-1 DNA. DNA binding activities of wild-type p53 (wtp53), p53pro248 and p53pro273 mutants are indicated.CC BY · PubMed Central
Figure 2 MCP-1 induction by TNF-α after reconstitution of wild-type p53 activities. 4Bv (A) and BT2E (B) cells were cultivated at 37°C or shifted to 32°C overnight. Stimulation was done with TNF-α for 4 h or 6 h. Total cellular RNA was separated in a 1% agarose gel and transferred to a Gene screen Plus membrane. The filter was subsequently hybridized with a p21, MCP-1 and c-myc cDNA probe. The positions of the 28S and 18S ribosomal RNA are indicated.
Figure 2 MCP-1 induction by TNF-α after reconstitution of wild-type p53 activities. 4Bv (A) and BT2E (B) cells were cultivated at 37°C or shifted to 32°C overnight. Stimulation was done with TNF-α for 4 h or 6 h. Total cellular RNA was separated in a 1% agarose gel and transferred to a Gene screen Plus membrane. The filter was subsequently hybridized with a p21, MCP-1 and c-myc cDNA probe. The positions of the 28S and 18S ribosomal RNA are indicated.CC BY · PubMed Central
Figure 3 Temperature shifting does not affect the cell cycle or TNF-α signaling. (A) 4Bv cells were maintained at 37°C or 32°C overnight, followed by treatment with or without TNF-α for 6 h. Flow-cytometric analysis was performed on DAPI/SR 101 stained cells to determine the percentage of 4Bv cells in different cell cycle phases (G1, S, G2/M). Mean values (columns) and standard deviations (bars) are given for three independent experiments. Steady state expression (B) and phosphorylation (C) of p38 MAP kinase was analyzed after treatment of 4Bv cells (at 37°C or 32°C) with TNF-α as indicated. Total cellular protein (50 μg) was separated in a 12% SDS-PAGE gel. After electrotransfer, the filter was consecutively incubated with antibodies as indicated and re-probed with anti-actin antibody as loading-controls. (-): untreated control cells; (15')/(30')/(60'): cells treated with 250 U/ml of TNF-α for the indicated time.
Figure 3 Temperature shifting does not affect the cell cycle or TNF-α signaling. (A) 4Bv cells were maintained at 37°C or 32°C overnight, followed by treatment with or without TNF-α for 6 h. Flow-cytometric analysis was performed on DAPI/SR 101 stained cells to determine the percentage of 4Bv cells in different cell cycle phases (G1, S, G2/M). Mean values (columns) and standard deviations (bars) are given for three independent experiments. Steady state expression (B) and phosphorylation (C) of p38 MAP kinase was analyzed after treatment of 4Bv cells (at 37°C or 32°C) with TNF-α as indicated. Total cellular protein (50 μg) was separated in a 12% SDS-PAGE gel. After electrotransfer, the filter was consecutively incubated with antibodies as indicated and re-probed with anti-actin antibody as loading-controls. (-): untreated control cells; (15')/(30')/(60'): cells treated with 250 U/ml of TNF-α for the indicated time.CC BY · PubMed Central
Figure 4 Expression of MCP-1 in Li Fraumeni fibroblasts and after p53 knockdown in A172 cells. (A) RT-PCR of MCP-1 and GAPDH in Li Fraumeni cells (MDAH041) in passage 8 (p:8, p53 mut/wt) and passage 160 (p:160, p53 mut/mut), respectively. Cells were treated with 250 U/ml of TNF-α for 6 h (+). Untreated control cells: (-). (B) Western blot analysis of p53 in MDAH041 cells (p:8) and (p:160) treated with TNF-α (250 U/ml) (+) for 6 h. (-): untreated control. Cytosolic extracts (50 μg per lane) were separated in a 12% SDS-PAGE. Actin confirms equal loading. (C) A172 cells were transiently transfected with pSUPER-p53 or with the empty pSUPER vector. After 24 h, cells were stimulated with TNF-α for additional 5 h. Cells were harvested and Western blot analysis was performed. Filters were probed with anti-p53 (DO-1) (see also panel B). (D) 4 μg of total RNA were separated in a 1% agarose gel and transferred to a Gene screen Plus membrane. The filter was subsequently hybridized with a MCP-1 cDNA probe. Hybridization of the same filter with a cDNA probe coding for the housekeeping gene β-actin confirmed equal loading. The positions of the 28S and 18S ribosomal RNA are indicated.
Figure 4 Expression of MCP-1 in Li Fraumeni fibroblasts and after p53 knockdown in A172 cells. (A) RT-PCR of MCP-1 and GAPDH in Li Fraumeni cells (MDAH041) in passage 8 (p:8, p53 mut/wt) and passage 160 (p:160, p53 mut/mut), respectively. Cells were treated with 250 U/ml of TNF-α for 6 h (+). Untreated control cells: (-). (B) Western blot analysis of p53 in MDAH041 cells (p:8) and (p:160) treated with TNF-α (250 U/ml) (+) for 6 h. (-): untreated control. Cytosolic extracts (50 μg per lane) were separated in a 12% SDS-PAGE. Actin confirms equal loading. (C) A172 cells were transiently transfected with pSUPER-p53 or with the empty pSUPER vector. After 24 h, cells were stimulated with TNF-α for additional 5 h. Cells were harvested and Western blot analysis was performed. Filters were probed with anti-p53 (DO-1) (see also panel B). (D) 4 μg of total RNA were separated in a 1% agarose gel and transferred to a Gene screen Plus membrane. The filter was subsequently hybridized with a MCP-1 cDNA probe. Hybridization of the same filter with a cDNA probe coding for the housekeeping gene β-actin confirmed equal loading. The positions of the 28S and 18S ribosomal RNA are indicated.CC BY · PubMed Central
Figure 5 p53 binds to the enhancer region of MCP-1 in vivo. (A) DNA sequence of the 5'-regulatory region of the MCP-1 gene (-2550 to -2250) indicating MCP-1 specific primer pairs used for the chromatin immunoprecipitation (ChIP) assay by arrows. The p53 binding site is marked with bold letters. (B) 4Bv cells were maintained at 37°C or shifted to 32°C for 5 h and stimulated with TNF-α for additional 5 h. Cells were harvested for chromatin immunoprecipitation (ChIP) assay as described in Materials and Methods. Samples were subjected to immunoprecipitation without antibody (no ab), with p53 antibody or rabbit IgG (IgG); total lysate was used as a control for PCR amplification (input). (B, left panel) p53 binding was tested by using MCP-1 specific primers; (B, right panel) p21 primers were used as a positive control. Untreated control cells (-); cells treated with 250 U/ml of TNF-α for 5 h (+).
Figure 5 p53 binds to the enhancer region of MCP-1 in vivo. (A) DNA sequence of the 5'-regulatory region of the MCP-1 gene (-2550 to -2250) indicating MCP-1 specific primer pairs used for the chromatin immunoprecipitation (ChIP) assay by arrows. The p53 binding site is marked with bold letters. (B) 4Bv cells were maintained at 37°C or shifted to 32°C for 5 h and stimulated with TNF-α for additional 5 h. Cells were harvested for chromatin immunoprecipitation (ChIP) assay as described in Materials and Methods. Samples were subjected to immunoprecipitation without antibody (no ab), with p53 antibody or rabbit IgG (IgG); total lysate was used as a control for PCR amplification (input). (B, left panel) p53 binding was tested by using MCP-1 specific primers; (B, right panel) p21 primers were used as a positive control. Untreated control cells (-); cells treated with 250 U/ml of TNF-α for 5 h (+).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 1

  1. Donehower LA, Bradley A: The tumor suppressor p53. Biochim Biophys Acta. 1993, 1155: 181-205.

Cited by

See all 63

Metadata

Authors
Hacke, K., Rincon-Orozco, B., Buchwalter, G., Siehler, S. Y., Wasylyk, B., Wiesmüller, L., & Rösl, F.
Affiliations
  • German Cancer Research Center (DE)
  • Institut de génétique et de biologie moléculaire et cellulaire (FR)
  • Universität Ulm (DE)
Corresponding author
Rösl, Frank
Venue
Molecular Cancer
Published
2010-04-20
Volume
9
Issue
1
Pages
82-82
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2145414107
Cited by
63
References
61
Citations by year
2025: 4 · 2024: 3 · 2023: 2 · 2022: 7 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 8 · 2012: 6
FWCI
2.53
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Wayne State University
  • Deutsches Krebsforschungszentrum
  • Deutsche Forschungsgemeinschaft
  • Institut National de la Santé et de la Recherche Médicale
  • Weizmann Institute of Science
  • Centre National de la Recherche Scientifique
  • Deutsche Krebshilfe
  • Institut National Du Cancer
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
MCP-1, p53, chemokine transcription, human papillomavirus, E6 oncoprotein, E7 oncoprotein, TNF-α, keratinocytes, p53 binding sites, temperature-sensitive p53 mutant, Li-Fraumeni syndrome, immune surveillance, carcinogenesis, monocyte/macrophage infiltration
MeSH terms
Cell Line, Cell Transformation, Neoplastic, Electrophoresis, Polyacrylamide Gel, Enhancer Elements, Genetic, Gene Expression Regulation, Humans, Tumor Necrosis Factor-alpha, Blotting, Northern, Blotting, Western, Keratinocytes, Tumor Suppressor Protein p53, Chemokine CCL2, Reverse Transcriptase Polymerase Chain Reaction, Electrophoretic Mobility Shift Assay, Chromatin Immunoprecipitation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulation of MCP-1 chemokine transcription by p53. https://app.cochat.ai/papers/10.1186/1476-4598-9-82
The paper
Hacke, K., Rincon-Orozco, B., Buchwalter, G., Siehler, S. Y., Wasylyk, B., Wiesmüller, L., & Rösl, F. (2010). Regulation of MCP-1 chemokine transcription by p53. Molecular Cancer. https://doi.org/10.1186/1476-4598-9-82

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.